Preparation of compound AN12541
Synthetic Scheme:
To a mixture of compound I (3.50 g, 14.58 mmol, 1. mol, 1.20 Eq) dropwise at 0 °C. The mixture was warmed to 25 °C for 1 h. The mixture was poured into ice water and adjusted to pH 4-5, the aqueous phase was extracted with dichloromethane (2x1000 mL*2). The combined organic phase was washed with saturated brine (2x2000), dried with anhydrous Na 2 SO 4 , filtered and concentrated in vacuum, purified via column chromatography (EtOAc/petroleum ether = 5% ~ 10%) to afford compound II as light yellow oil (480.00 g, 1.33 mol, 74% yield).
A mixture of compound II (480.00 g, 1.33 mol, 1.00 eq), BPD (354.63 g, 1. To a mixture of compound V (1.00 g, 3.94 mmol, 1.00 eq) and compound VI (1.51 g, 7.88 mmol, 2.00 eq) in DMF (20 mL), was added K 2 CO 3 (1.09 g, 7.88 mmol, 2.00 eq) in one portion at 20 °C. The mixture was warmed to 80 °C. After 4h the mixture was cooled to RT. Water was added and the mixture was extracted with EtOAc (3x100 mL). The combined organic phase was washed with saturated brine (2x200 mL), dried with anhydrous Na 2 SO 4 , filtered and concentrated in vacuo to afford compound VII (2.00 g, crude).
To a mixture of compound VII (1.50 g, 3.52 mmol, 1.00 eq) in EtOH (30 mL), was added hydroxylamine hydrochloride (366.91 mg, 5.28 mmol, 1.50 eq), KOAc (690.91mg, 7.04 mmol, 2.00 eq). The mixture was warmed to 50 °C. After 2h the EtOH was removed in vacuo. The mixture was extracted with EtOAc (3x100mL). The combined organic phase was washed with saturated brine (2x200 mL), dried with anhydrous Na 2 SO 4 , filtered and concentrated in vacuo, the residue was purified via prep-HPLC to afford compound AN12855 (868.00 mg, To a solution of compound II (10.20 g, 41.12 mmol, 1.00 Eq) in THF/H 2 O (80/80 mL) was added NaIO 4 (43.98 g, 205.60 mmol, 5.00 Eq) and the mixture was stirred at r.t. After 3 h the reaction was filtered. The filtrate was extracted with EtOAc. The organic layer was washed with brine, dried over Na 2 SO 4 and concentrated (5.90 g, 35.56 mmol, 87% yield).
The mixture of compound III (800.00 mg, 4.82 mmol, 1.00 Eq) and compound IV (598.58 mg, 4.82 mmol, 1.00 Eq) in EtOH (30 mL) was stirred at 50 °C overnight. The solvent was removed in vacuo to give compound V (1.3 g, crude).
To a mixture of compound V (800.00mg, 3.15mmol, 1.00 Eq) and compound VI (907.72 mg, 4.72 mmol, 1.50 Eq) in DMF (30 mL), was added K 2 CO 3 (870.37 mg, 6.30 mmol, 2.00 Eq) in one portion at r.t. under N 2 and the reaction mixture was heated to 80 °C . After 2 hthe mixture was cooled to r.t. The residue was poured into water and the mixture was extracted with EtOAc.
The organic phase was washed with saturated brine, dried with anhydrous Na 2 SO 4 , filtered and concentrated in vacuo.
The residue was purified via silica gel chromatography to afford compound VII (900.00 mg, crude). 
Sequencing of clinical isolates
DNA was extracted from the clinical isolates using the MasterPure Gram positive DNA purification kit (Lucigen) following heat inactivation at 90°C for 60 min. DNA was stored at 4°C. PCR was performed using the following primer pairs fabG1-inhA (TB-FabG1-MMF1, TCAATACACCCGCAGCCA and InhA-R1, GTGATACCCCACCGAAATGC), or katG (TBKatG-MMF3, TCTATACCGGACTACGCC and TB-KatG-MMR4, TGGACCGTTTCGACAA).
Reactions were performed with Platinum Taq DNA polymerase High Fidelity (Invitrogen) in the presence of 5% (v:v) DMSO and 1M betaine (pH 9) (Sigma). Regional sequence of the resultant amplicons was performed using nested primer sets. Mutations in katG were associated with isoniazid resistance for all three strains of interest. Low-level isoniazid resistance in TN5904
was associated with a previously described G944C mutation (KatG S315T ) previously shown to retain catalase-peroxidase activity in vitro (Ando AAC 2010). High level isoniazid resistance was associated with a frameshift mutation in katG (∆G803), resulting in premature termination at AA343 in strain M70. We repeatedly failed to amplify the katG region from strain M28, 
